Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
PAION discontinues European Remimazolam Phase III Trial in cardiac surgery patients due to insufficient recruitment
PAION reports about positive pre-NDA meeting with Japanese authority PMDA
PAION successfully completes patient recruitment in Phase III study with Remimazolam for procedural sedation during colonoscopy
PAION reports positive remimazolam headline data in pivotal U.S. Phase III study in procedural sedation for colonoscopy
PAION grants Cosmo Pharmaceuticals Remimazolam license in the U.S. and Cosmo becomes largest Shareholder of PAION AG
PAION successfully completes patient recruitment in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy